ArticleJCO global oncology2026
Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings.
Article in JCO global oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeGenomic assays are commonly used to predict breast cancer recurrence but remain inaccessible in low-resource settings, often leading to unnecessary chemotherapy. We previously optimized a LASSO-penalized regression model incorporating quantitative clinicopathologic features to predict genomic risk. Here, we present validation and clinical utility in an international cohort.
methodsWe retrospectively analyzed patients with early-stage hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer treated in Chicago and Rio de Janeiro. Model accuracy for predicting high Oncotype DX (ODX) scores was evaluated using area under the receiver operating characteristic curve (AUROC) in Chicago cohorts. Survival outcomes-disease-free interval (DFI), disease-free survival (DFS), and overall survival (OS)-were compared by Kaplan-Meier and Cox regression using a predefined threshold for high-risk disease. Adjusted models examined chemotherapy benefit by predicted risk. Estimated cost was compared between testing strategies and chemotherapy allocation in Brazil and the United States. The study was approved by the Brazilian Research Ethics Committee on October 24, 2024, under CAAE number 67993323.6.0000.5274. Due to the retrospective nature of the study, which involved only data collection from electronic medical records, the requirement for informed consent was waived by the Ethics Committee. Additionally, the study is covered under Institutional Review Board 22-0707 at the University of Chicago.
resultsWe included 1,566 patients from Chicago and 296 from Rio de Janeiro. The estrogen receptor/progesterone receptor/Ki-67 model showed strong performance for ODX prediction (AUROC 0.81 and 0.91).Compared with high-risk patients, low-risk patients had superior 5-year DFI (98.0%
conclusionOur model accurately predicted recurrence and outcomes across US and Brazilian cohorts, supporting treatment de-escalation in low-risk patients and promoting equitable care where genomic testing is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.